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Objective. Lower third molar removal provides a clinical model for studying analgesic drugs. The present study’s aim was to
compare the clinical efficacy of sublingual ketorolac and sublingual piroxicam in managing pain, trismus and swelling after
lower third molar extraction in adult volunteers.
Study Design. In this double-blinded, randomized, crossover investigation, 47 volunteers received for 4 days ketorolac
sublingually (10 mg 4 times daily) and piroxicam sublingually (20 mg once daily) during 2 separate appointments after
lower third molar extraction of symmetrically positioned lower third molars. A surgeon evaluated objective parameters
(surgery duration, mouth opening, rescue analgesic medication, and facial swelling) and volunteers documented
subjective parameters (postoperative pain and global evaluation), comparing postoperative results for a total of 7 days
after surgery. The means of the objective and subjective parameters were compared for statistical significance (P  .05).
Results. Volunteers reported low pain scores during the postoperative period when treated with either sublingual ketorolac or
piroxicam. Also, volunteers ingested similar amounts of analgesic rescue medication (paracetamol) when they received either
drug sublingually (P  .05). Additionally, values for mouth openings measured just before surgery and immediately after
suture removal 7 days later were similar among volunteers (P  .05), and the type of nonsteroidal antiinflammatory drug
(NSAID) used in this study showed no significant differences between swellings on the second or seventh days after surgery (P
 .05).
Conclusions. Pain, trismus, and swelling after lower third molar extraction, independent of surgical difficulty, were
successfully controlled by sublingual ketorolac (10 mg 4 times daily) or sublingual piroxicam (20 mg once daily), and no
significant differences were observed between the NSAIDs evaluated. (Oral Surg Oral Med Oral Pathol Oral Radiol 2012;114:
27-34)Pain resulting from the trauma of lower third molar
extraction is a clinical model commonly used to study
acute pain. Additionally, many patients require lower
third molar surgery making this procedure quite com-
mon. More specifically, the postoperative pain experi-
enced by the patient is typically moderate to severe
lasting for 24 hours.1 That is, pain from lower third
molar extraction reaches its maximum intensity shortly
after the end of surgery (2-4 h), and, in most cases,
patients require some type of pain management.2
Besides pain, swelling, and limited articulation of the
temporomandibular joint associated with inflamma-
tion, there are further undesirable consequences for
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of work or dietary limitations.3-5 In general, treat-
ment for pain, trismus, and swelling after lower third
molar surgery may include nonsteroidal antiinflam-
matory drugs (NSAIDs).3,5-7
Most NSAIDs function by inhibiting cyclooxygen-
ase (COX) and therefore, among other actions, ulti-
mately result in an inhibition of prostaglandin produc-
tion.8-10 Currently, 3 isoforms of COX are recognized.
One isoform, COX-1, is a constitutive form expressed
in almost all tissues. Another isoform, COX-2, also
known as prostaglandin-endoperoxide synthase 2, is
predominantly induced and constitutively expressed in
a limited number of tissues (renal medulla, prostate,
brain, and endothelium).8-12 The isoenzyme COX-2
stimulates the synthesis of proinflammatory prostaglan-
dins.3,5,8,10 The third isoform of COX, COX-3, a COX-
1–derived protein, is most abundant in the cerebral
cortex and heart.12,13 COX-3 inhibition may represent
the primary central mechanism by which NSAIDs such
as acetaminophen and dipyrone decrease pain and pos-
sibly fever.13,14 Finally, in accordance to their relative
27
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fied as nonselective, COX-2 preferential, or COX-2
selective.15,16 Both ketorolac and piroxicam are nonse-
lective COX inhibitors and both NSAIDs competitively
block COX, thereby inhibiting prostaglandin synthesis.
Various studies have investigated the efficacy of the
more traditional NSAIDs. These NSAIDs that have
been examined include diclofenac, ibuprofen, meloxi-
cam, piroxicam, and ketorolac, which are all nonselec-
tive for COX-2 inhibition, and valdecoxib, celecoxib,
rofecoxib and etoricoxib, which are all selective for
COX-2 inhibition. Furthermore, all of these studies
administered NSAIDs orally.3,6,10,17-20
Besides oral administration, NSAIDs have been ad-
ministered sublingually. There are certain advantages
of administering analgesics sublingually compared
with oral administration. In particular, sublingual ad-
ministration of a drug can relieve pain faster than oral
administration because the sublingual administration
route avoids the gastrointestinal tract and also the first
passage of the drug in the liver where some of the drug
would be metabolized.21 Also, some patients find tak-
ing medications sublingually to be more comfortable
than taking medications orally. Finally, in some coun-
tries some drugs are available only in sublingual form.
More precisely, ketorolac is available only in a fast-
dissolving sublingual form in Brazil, whereas piroxi-
cam is available in both sublingual and oral forms. Both
ketorolac and piroxicam are currently the only 2
NSAIDs that are available in sublingual form in Brazil.
Currently, little clinical research has investigated the
efficacy of sublingually administering the nonselective
NSAIDs, piroxicam and ketorolac, to manage pain,
trismus and swelling resulting from the trauma of lower
third molar surgery. To the best of our knowledge, no
one has compared the use of these 2 NSAIDs admin-
istered sublingually. Our laboratory recently published
a study that investigated and compared the clinical
efficacy of sublingual piroxicam and oral piroxicam
after lower third molar extraction, and it was found that
both sublingual piroxicam and oral piroxicam were able
to successfully control postoperative pain, trismus, and
swelling.22 Moreover, some volunteers preferred taking
the fast-dissolving sublingual administration compared
with oral administration. The present study followed
the previous study and investigated the clinical efficacy
of sublingual piroxicam and sublingual ketorolac after
lower third molar extraction in a completely separate
patient group.
It was hypothesized that both ketorolac and piroxi-
cam would have similar clinical efficacy when admin-
istered sublingually in volunteers after lower third mo-
lar surgery. The aim of this was to compare the clinical
efficacy of sublingual ketorolac and sublingual piroxi-cam in managing pain, trismus, and swelling after
lower third molar extraction in adult volunteers.
MATERIALS AND METHODS
This study used a double-blinded, randomized, cross-
over design. In brief, only 1 side of the mandibular jaw
was operated on at a time, and these surgeries were
performed over the course of 2 visits separated by 1-2
months.3,4,20,23-25 During each volunteer’s first appoint-
ment, the subject randomly received either ketorolac or
piroxicam sublingually for postoperative pain relief.
During the volunteer’s second appointment, the drug
not used previously was then administered in a cross-
over manner.
The Ethics Committee of the Bauru School of Den-
tistry, University of São Paulo, approved the protocol
of this study (#105/2006). Each of the volunteers pro-
vided written informed consent during the pretreatment
screening period. Eligibility criteria included volun-
teers aged 18 years who had 2 lower third molars in
similar positions as observed using panoramic radiog-
raphy, each requiring extraction.26,27 Exclusion criteria
included: systemic illness and inflammation or infection
at the extraction sites; gastrointestinal bleeding or ulcer-
ation; cardiovascular and hepatic diseases; and any known
allergies to the local anesthetic used, paracetamol, aspirin,
ketorolac, piroxicam, or any other NSAID. Pregnant
women also were excluded from the study. Instructions
for not using antidepressants, diuretics, aspirin, or antibi-
otics 7 days before surgery were given to the volunteers,
avoiding possible hemorrhage or other possible unwanted
interactions with the drugs used in this investiga-
tion.3,4,20,23-25
One surgeon performed all surgical operations and
postoperative controls. Before surgery, all volunteers
received local anesthetic blockade of buccal, lingual,
and inferior alveolar nerves via one 1.8-mL cartridge of
4% articaine with 1:200,000 epinephrine.25 When an-
esthesia of the inferior lip was achieved, an additional
0.9 mL volume of the same anesthetic solution was
injected into the mucosa to guarantee homeostasis and
anesthesia of the site. Next, the extraction of every third
molar followed a standard surgical protocol.25 Imme-
diately after the extraction, each surgical site was thor-
oughly irrigated, suctioned, and sutured.3,4 A second
dentist naive to the details of the surgery then instructed
each patient how to take the fast-dissolving dosage
form of ketorolac or piroxicam sublingually (randomly
assigned by coin flip). During the next visit the patient
was instructed how to take the second NSAID sublin-
gually that was not administered in the first trial. At no
time were volunteers given antibiotics.
After surgery, volunteers remained in the clinic for
the first postoperative hour. During this time, the local
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aim of this study was to investigate and compare the
efficacy of either ketorolac or piroxicam sublingually
to guarantee a painless postoperative period. It was
not the aim of this study to determine or compare the
onset of pain management by ketorolac and piroxi-
cam sublingually.
Briefly, for 4 consecutive days the NSAID adminis-
tration protocol was 1 10-mg tablet of fast-dissolving
dosage form of ketorolac taken sublingually 4 times
daily (every 6 h) or 1 20-mg tablet of fast-dissolving
dosage form of piroxicam taken once daily. Volunteers
were aware that 2 different NSAIDs would be admin-
istered and that 1 drug would be taken once daily,
whereas the other drug would be taken 4 times daily,
yet each patient remained naive to what drugs were
used.
Additionally, oral rescue analgesic medication was
available to any volunteer as needed throughout this
study; for this purpose, 750-mg tablets of paracetamol
were provided to all volunteers.3,4,20,23-25 In general,
volunteers recorded the date and time at which rescue
medication was consumed. They were also instructed
not to interrupt the use of the principal medication
(ketorolac or piroxicam), even if they consumed the
rescue analgesic medication (paracetamol).
The following parameters were collected and assessed.
Surgery duration (min) after anesthetic administration,
specifically the period between the first incision and the
last suture, was cataloged.3-5 Subjective postoperative
pain evaluations were documented with the aid of a
100-mm long visual analog scale (VAS), with 0 repre-
senting “no pain” and 100 representing “worst pain imag-
inable.”3,4,28 The intensity of postoperative pain was
chronicled at 15-minute intervals for the first 60 postop-
erative minutes, and 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24,
48, 72, and 96 hours after the end of the surgery as
evaluated by the volunteers.4,20,23-25,29 Time (h) to first
rescue analgesic medication and total amount (mg) of
rescue analgesic medication ingested during the postoper-
ative period was documented by each volunteer. Also, the
surgeon measured and recorded the mouth opening dis-
tance (in mm) between the mesial-incisal corners of the
upper and lower right central incisors at maximum open-
ing of the jaws before the surgery, during the second
postoperative day, and at the moment of suture removal
(seventh postoperative day). The postoperative ability to
open the mouth was expressed as a percentage of preop-
erative measurements.4,5 The surgeon also measured and
recorded facial swelling during the second and seventh
postoperative days.5 This method produced a single value
for each volunteer, namely, the sum of the following
measurements: the distance (mm) between the lateral cor-
ner of the eye and the angle of the mandible, the distance(mm) between the tragus and the outer corner of the
mouth, and the distance (mm) between the tragus and the
soft tissue pogonion. The preoperative sum of these 3
measurements was considered to be the baseline value.
The difference between the sum of the postoperative mea-
surements and the baseline value indicated the facial
swelling for that day. Each volunteer documented inci-
dence, type, and severity of adverse reactions (gastroin-
testinal irritation, nausea, vomiting, bleeding, allergy,
headache, dizziness, sleepiness, and any other kind of
reaction).28 Each volunteer also rated his or her global
evaluation of the postoperative period (seventh postoper-
ative day) using a 5-level Likert scale. The format of the
Likert items was “excellent,” “very good,” “good,” “fair,”
or “poor.”30
A statistician used paired t tests to compare the
duration of the entire surgeries. The nonparametric
Wilcoxon test was used to assess the parameters “post-
operative pain” and “rescue analgesic medication.” The
statistician also tested the “mouth opening” and “facial
swelling” parameters for normal distribution and these
parameters were compared using an analysis of vari-
ance followed by the Tukey test for multiple compari-
sons. Statistical significance was set at P  .05. Data
are represented as a mean  SEM.
RESULTS
In this crossover study, a total of 47 volunteers, with 28
women and 19 men, were investigated. Their ages
ranged from 18 to 37 years with an average age of 23
years. No significant differences were found between
male and female volunteers, and no correlation was
found between age and any variable tested (data not
shown).
Each volunteer experienced approximately the same
magnitude of surgical trauma on each side of the man-
dibular jaw (Table I). However, among the volunteers
the surgical trauma varied, with some volunteers re-
quiring osteotomy. More explicitly, the need for osteot-
omy was determined by radiographic analysis con-
firmed by visual inspection during surgery, and each
patient that required osteotomy required bilateral os-
teotomies. Additionally, volunteers were randomly as-
signed ketorolac or piroxicam after their first surgery
regardless of their need for osteotomy.
As a part of an ad hoc analysis, the 47 volunteers
were subdivided into 2 groups: 25 volunteers without
the necessity of osteotomy and 22 with the need for
an osteotomy. The surgeries requiring osteotomy
lasted an average 19.88  1.29 minutes and 19.60 
1.86 minutes for volunteers taking ketorolac and
piroxicam, respectively. Volunteers who required no
osteotomy had surgeries lasting 10.20  0.29 min-
utes and 10.14  0.29 minutes for those who took
ually (
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differences between the mean durations of the 2
surgeries in each volunteer were observed (P  .05).
However, there was a significant difference in the
mean duration of operations performed with and
without bone removal (P  .05), indicating that the
surgeries involving the more time-consuming osteot-
omy were more aggressive (data not shown). Overall,
the durations of all surgeries were brief.
In the postoperative pain scores documented by each
volunteer, no significant difference between piroxicam
and ketorolac existed (P .05; Fig. 1). Furthermore, all
scores of pain recorded were minimal when compared
with the full 100-mm-length VAS.
Likewise, the average total amount of analgesic res-
cue medication consumed by volunteers was quite
small, being on average 2 tablets per person in each
group tested during the entire time period of the study.
When volunteers received ketorolac, they showed a
trend to consume more rescue medication compared
with piroxicam, but the difference was not statistically
significant (P  .05; Table II).
There was no significant difference in the time of
ingestion of the first rescue medication when volun-
teers were medicated with either ketorolac or piroxi-
cam (P  .05; Table II). When volunteers received
piroxicam, they showed a trend to take their rescue
medication earlier then when these volunteers re-
ceived ketorolac, but this difference was not statis-
tically significant (P  .05; Table II).
There was only a major limitation of the volun-
teers’ mouth opening during the second day. During
the seventh day after surgery, the values for mouth
opening measurements returned to baseline values
(P  .05; Table II). Similar mouth openings were
recorded during the second and seventh postopera-
tive days whether volunteers took sublingual ketoro-
lac or sublingual piroxicam. Additionally, no signif-
icant differences in the mouth opening parameters
were observed between the groups with and without
osteotomy (data not shown).
A similar result was observed for the values taken for
swelling during the second and seventh day after sur-
Table I. Study variables
Study variable P
Time of operation (min) 14
Local anesthesia used during surgery (mL)* 2
Mouth opening (mm)—preoperative period
Facial contour (mm)—preoperative period
Temperature (°C)—preoperative period 3
*Local anesthesia: 1 cartridge contained 1.8 mL of 4% articaine wit
patient was treated with ketorolac or piroxicam administered sublinggery. Volunteers showed no significant differences be-tween the groups. Swelling tended to be increased
during the second day, which returned to baseline mea-
surements during the seventh day (P  .05; Table II),
but this increase in swelling was not statistically sig-
nificant and was the same regardless of the NSAID
taken sublingually.
Additionally, 5 volunteers who received piroxicam
documented adverse reactions, with 4 volunteers re-
porting drowsiness and 1 reporting mild bleeding at the
site of surgery (Table II). Seven other volunteers noted
adverse reactions when they received ketorolac (Table
II). Specifically, these volunteers reported gastric dis-
comfort (4 volunteers), nausea (1 volunteer), headache
(1 volunteer), and chest pain (1 volunteer). None of the
volunteers who reported adverse reaction for 1 drug
reported adverse reactions with the other drug. There
was no significant difference in the number of adverse
side effects reported between the volunteers when using
piroxicam or ketorolac (P  .05; Table II).
There were no significant differences observed be-
tween the volunteers’ global evaluations for piroxicam
and ketorolac (Fig. 2). According to the volunteers’
global evaluations of their postoperative period, both
NSAIDs were classified as “good,” “very good,” and
“excellent” in general, and no volunteers, regardless of
osteotomy, classified the postoperative period as
“poor.” When osteotomy was necessary, one volunteer
who took piroxicam and another volunteer who took
ketorolac classified the period as “fair.”
DISCUSSION
This study investigated the clinical efficacy of man-
aging postoperative pain using 2 NSAIDs, ketorolac
and piroxicam, which were administered sublin-
gually after the lower third molar was extracted
under local anesthesia. The degree of difficulty of the
surgical procedure and the local trauma caused by
the surgery varied among the volunteers, depending
on whether it was necessary to remove bone tissue to
extract the lower third molars. Surgical trauma on
either side of the jaw in each volunteer was not signif-
icantly different. However, there was a difference in
surgical trauma observed among those who received
m Ketorolac P value
.60 14.73  1.34 .432
.04 2.72  0.03 .285
47  2 .122
125  1 .158
.1 36.1  0.1 .412
,000 epinephrine. No significant differences were found when each
P  .05) during 2 surgeries separated by an interval of 1-2 months.iroxica
.69  1
.74  0
48  2
123  3
6.1  0
h 1:200osteotomy and those who did not. However, after an ad
ted as
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visions (with or without osteotomy), no potential con-
founding variables were found. Because the treatment
groups were randomly assigned, necessity for osteot-
omy was evenly distributed between treatment groups
and there was no need to adjust for volunteers with
osteotomy.
Lower third molar surgery is a well accepted and
commonly used procedure to evaluate clinical efficacy
of anesthetics and antiinflammatory drugs.20,23 When
patients receive no analgesic medication, they report a
pain score of 8 on a VAS from 0 to 10 with 0 repre-
senting no pain and 10 representing worst pain imag-
inable.1 Clearly, managing pain for these surgeries is
necessary, and the present study did not use a placebo
in a subset of volunteers as a negative control. Further-
more, in this study the same surgical procedure was
performed on both sides of the jaw on 2 separate
occasions in the same volunteer and then each side of
the jaw was compared with the other, thus avoiding
individual variations.26,27 In this way each volunteer
Fig. 1. Mean pain scores (mm) recorded by volunteers (n 4
0.75, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, 12, 16, 24, 48, 72, and 96
Two drugs, ketorolac (10 mg 4 times daily) and piroxicam (20
days and were used in a double-blind, randomized, crossove
were not significantly different from one another (P  .05; Tu
.05 ketorolac versus ketorolac at time 6 h. Data are represen
Table II. Outcome variables during the second and se
Outcome variable Pir
Mouth opening (%)*—2nd day 77.4
Mouth opening (%)*—7th day 93.0
Swelling (mm)†—2nd day 6.0
Swelling (mm)†—7th day 0.6
Temperature (°C)—2nd day 36.1
Temperature (°C)—7th day 36.1
Total amount of rescue medication (mg)‡ 1069
Time to first rescue medication (h) 13.17
Reports of adverse reactions
*Mouth opening and swelling are relative to preoperative values (T
†Swelling values are the differences of the second or seventh po
(Table I).
‡Rescue medication provided was paracetamol (750-mg tablets).served as his or her own control.The method used in this study to measure swelling is
widely accepted in the literature.5,21 The benefits of this
method lie in its simplicity. It is noninvasive, cost-
effective, and timesaving and provides numeric data for
determination of soft tissue contour changes. The re-
sults of this protocol showed changes in facial soft
tissue contours on the second and seventh postoperative
days, corroborating the results observed by Calvo et
al.20 (meloxicam) and Graziani et al.21 (piroxicam). On
the seventh postoperative day, for both groups, the
magnitude of swelling was far less than that observed
on the second postoperative day, with measures close to
the baseline (preoperative) values.
Closely related to swelling, mouth opening in the 2
postoperative periods was the same among all groups.
These data are in agreement with other studies that used
other NSAIDs,3,4,20,21 which showed the effectiveness
of NSAIDs in controlling pain, swelling, and trismus
after lower third molar extraction.
In the present study, the length of time that each
NSAID needed to completely relieve pain was not
the aid of a 100-mm-length visual analog scale at 0.25, 0.50,
after the end of the surgery for lower third molar extraction.
ce daily), were administered sublingually for 4 postoperative
er. During each time point studied, piroxicam and ketorolac
st); ‡ P  .05 piroxicam versus piroxicam at time 0 h; * P 
mean  SEM.
days after lower third molar extraction
Ketorolac P value
77.6  2.5 .310
88.8  2.7 .056
3.2  0.4 .182
1.8  2.7 .399
35.4  0.9 .141
36.1  0.2 .419
1372  243 .099
20.55  5.50 .089
7 .713
tive days from the facial contour during the preoperative period7) with
hours
mg on
r mann
key teventh
oxicam
 2.6
 2.6
 2.2
 3.5
 0.1
 0.1
 180
 3.32
5
able I).
stoperainvestigated. Rather, the aim of this study was to in-
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or piroxicam sublingually to guarantee a painless post-
operative period. Treating installed pain is markedly
different from preventing the onset of pain. By prevent-
ing the onset of pain, one avoids the central sensitiza-
tion of the involved pain pathways. An entirely differ-
ent experimental protocol would be necessary to
compare the onset of pain relief by ketorolac and pi-
roxicam, because volunteers were still under the effects
of local anesthesia from the surgery. As stated earlier,
in the present study, volunteers were given ketorolac
and piroxicam immediately after the end of surgery.25 It
was observed, however, that both NSAIDs were able to
relieve pain before the effects of the local anesthetic
dissipated.
Although various studies have investigated the effi-
cacy of the more traditional NSAIDs administered
orally, little clinical research has investigated the effi-
cacy of NSAIDs administered sublingually. One goal
of the present clinical study was to provide practitioners
with information regarding another option for pain
management. Although the protocol of this study did
not allow the investigation of the onset of pain relief,
Fig. 2. Global evaluations of ketorolac’s and piroxicam’s
efficacy during the seventh postoperative day was rated with
the use of a 5-level Likert scale by volunteers (n  47) who
received sublingual ketorolac (10 mg 4 times daily) and
sublingual piroxicam (20 mg once daily). The format of the
Likert items was “excellent,” “very good,” “good,” “fair,” or
“poor”. The volunteers’ ratings of each drug’s efficacy during
this postoperative period after lower third molar extraction
were collated and represented by 2 bar charts, with or without
osteotomy. Sublingual ketorolac and sublingual piroxicam
were depicted as 2 separate datasets, and no significant dif-
ferences were detected (Kruskal-Wallis 1-way analysis of
variance: P  .05).the sublingual administration of a drug can relieve painfaster than orally administered pain medication. Addi-
tionally, from a practical standpoint, if a patient is
experiencing nausea, a sublingual drug will not be
regurgitated and rendered ineffective, unlike standard
oral pain medication.
NSAIDs, including ketorolac and piroxicam, are not
completely free from adverse effects. Some individuals,
for example, exhibit allergic reactions to NSAIDs and
the use of ketorolac and piroxicam as well as other
NSAIDs is not recommended. Additionally, volunteers
with an increased risk for hepatic failure,31,32 peptic
ulcers,32 and gastrointestinal inflammation32 should
avoid using NSAIDs, including ketorolac and piroxi-
cam. Ketorolac tromethamine has been reported to have
a significant risk of adverse side effects. In a worldwide
evaluation of ketorolac from 1990 to 1993, 97 deaths
were associated with the use of ketorolac.33 According
to one datasheet for piroxicam “approximately 30% of
all patients receiving daily doses of 20 mg of piroxicam
experience[d] [adverse] side effects” and in some of
these remote cases these side effects were severe
enough to cause death.32 Consequently, volunteers
were excluded from this study if they had any history of
allergic reactions to any drugs, including NSAIDs, gas-
trointestinal bleeding or ulcerations, or cardiovascular
or hepatic diseases. In particular, the volunteers in this
study experienced few adverse side effects with either
sublingual ketorolac or sublingual piroxicam.
Previously, Trindade et al. found that both sublingual
and oral piroxicam were able to successfully control
postoperative pain prevention, trismus, and swelling.22
In that study, 53 volunteers received piroxicam admin-
istered orally or sublingually immediately after lower
third molar extraction, whereas in the present study 47
volunteers received ketorolac or piroxicam sublin-
gually. Ketorolac sublingually and piroxicam orally or
sublingually have similar clinical efficacy to control
pain, trismus, and swelling after lower third molar
surgery. In both studies, volunteers exhibited similar
values for mouth opening measured just before surgery
and immediately after suture removal 7 days later (P 
.05). Also, the type of NSAID used or the route of
administration used in the previous study22 showed no
significant differences between swellings on the second
or seventh postoperative days (P  .05). In sum, pain,
trismus, and swelling after lower third molar extraction,
independent of surgical difficulty, could be successfully
controlled by ketorolac administered sublingually (10
mg 4 times daily), piroxicam administered sublingually
(20 mg once daily), or piroxicam administered orally
(20 mg once daily), and no differences were observed
between the route of delivery used in the previous
study22 and the type of NSAID used in the present
study.
OOOO ORIGINAL ARTICLE
Volume 114, Number 1 Trindade et al. 33It was necessary to obtain consenting adults requir-
ing bilateral third molar extraction meeting the eligi-
bility criteria set forth in the protocol. With this aside,
the subjects enrolled were a random sampling of visi-
tors to our institution, which hopefully characterizes the
population at large. As in most clinical studies, it was
necessary to balance the available resources, such as
volunteers, time, and cost, with obtaining a sample size
big enough to both represent the population at large and
have enough statistical power to detect a clinically
significant difference. Therefore, the sample size used
in this study was determined by similar previously
published clinical studies and a balance of the available
resources for this study.3,4,20,22-25
Additionally, a post hoc power analysis was per-
formed investigating the likelihood that the lack of
observed differences between ketorolac and piroxicam
treatments was based on an actual parity rather than
simply being underpowered. In particular, patients expe-
riencing postoperative pain or chronic pain scoring 44
mm on a 100-mm VAS tend to describe pain as “mild” or
report minimal impact of their pain on daily activities.34
Therefore, it seems reasonable to assume an increase of 30
mm to be clinically significant, because this increase
would approximately place one of the treatments above a
pain scoring of 44 mm. A post hoc 2-tailed power analysis
(G-Power 3.1.2), given an error probability of 0.05% with
a sample size of 47 using a clinical difference in pain
scores of 30 mm with an  level of 0.05 yields a power
(1  ) of 0.9794.35 Also it should be noted that in the
present study the use of multiple comparisons should also
decrease the probability of a type II error.
This study confirmed the hypothesis that ketorolac
and piroxicam would effectively control inflammation
and postoperative pain after lower third molar extrac-
tion. The quantification of pain scores by VAS, the
amount of rescue medication taken by volunteers, and
the global evaluation of the drugs by the volunteers
remained the same regardless of the NSAID used. In
every parameter tested, when either ketorolac and pi-
roxicam were administered sublingually no significant
differences were observed.
CONCLUSION
The data from this study demonstrate that postoperative
pain, trismus, and swelling in volunteers subjected to
lower third molar extraction can be successfully con-
trolled by either ketorolac or piroxicam, both adminis-
tered sublingually. Additionally, in this study, volun-
teers experienced few adverse side effects with either
sublingual ketorolac or sublingual piroxicam.
The authors would like to thank Vera Lúcia Rufino for
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